Searched for
VIATRIS INC
S&P Global upgrades Biocon Biologics credit rating To 'BB+'Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' wi...- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Matrix Labs founder buys back Viatris' API business in IndiaViatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-par...
- On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-ShawBiocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...
- Biocon Biologics takes over Viatris' biosimilar biz in over 70 countriesBiocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...
- Viatris puts India API business on the blockHowever, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...
- Biocon raises $129 million from Kotak to fund biosimilars dealIndia's Kotak Mahindra Group asset management arm said on Wednesday it will invest 10.70 billion rupees ($129 million) in Biocon Ltd to hel...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Biocon Biologics allots equity shares worth Rs 2,205.63 crore to its parentAt the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be fun...
- Viatris buys Taparias' eyecare business for Rs 2,460 croreThe ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed f...
- Market movers: Biocon plunges 11%, Shankara Building jumps 10%When Biocon said it will buy US-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion that will increase debt o...
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
- Biocon Biologics, Viatris receive EC approval for biosimilar insulin as part KixelleBiocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-dev...
- Biocon tanks 4% as USFDA defers decision on Avastin biosimilar applicationBiocon's arm Biocon Biologics and Mylan, a subsidiary of Viatris Inc, have been informed by the USFDA of a deferred action on the BLA for M...
- USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...
- Biocon, Mylan's diabetic drug receives positive opinion from European Medicines AgencyBiocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...
Load More
